EGFR and breast cancer: In one breast cancer cell with high amplification of EGFR, sensitivity to its target drug, Gefitinib, was much higher than that in the other breast cancer cells, suggesting a possible correlation between EGFR-copy-gain and sensitivity to Gefitinib.